Pfizer has announced positive results from the EMPHASIS-HF trial2, which revealed that Inspra (eplerenone) reduces the incidence of new onset atrial fibrillation or flutter in patients with systolic heart failure and mild symptoms.
The Phase IIIB, multinational, randomised, double-blind, placebo-controlled and parallel-group trial enrolled 2,737 patients with chronic systolic heart failure and mild symptoms.
Go deeper with GlobalData
New onset atrial fibrillation or flutter occurred in 25 patients in the Inspra group, compared to 40 patients in the placebo group.
The study also reported that Inspra reduces the risk of cardiovascular mortality and morbidity in stable patients with left ventricular dysfunction.
Adverse reactions seen in patients who were given the drug include hyperkalemia, increased creatinine and hypertension.
In Japan, Inspra is approved for the treatment of hypertension.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
